The Cancer Letter

Inside information on cancer research and drug development

In Brief

Stephen Burley named leader of cancer pharmacology research at Rutgers Cancer Institute of New Jersey

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

STEPHEN BURLEY was named as co-program leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey.

Burley will work with co-program leader X.F. Steven Zheng, a university professor at Rutgers Robert Wood Johnson Medical School, in determining the mode of action and mechanism of resistance to anti-cancer agents and developing novel concepts and strategies for cancer treatment.

Burley has been a full research member of Rutgers Cancer Institute since 2013. He is the director of the Center for Integrative Proteomics Research, founding director of the Institute for Quantitative Biomedicine, and a distinguished professor of chemistry and chemical biology in the School of Arts and Sciences at Rutgers University. He also serves as director of the Research Collaboratory Structural Bioinformatics Protein Data Bank.

Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
By Matthew Bin Han Ong
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account